Replies to post #405141 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

But, a new presentation was delivered for the JPM conference!

Question why did you say IR told you data for P2/3b AD trial would be available before JP conference?

As opposed to some investor expectations, its just that the new presentation contained less information about the P2b/3 results, instead of more.

To top it off, Anavex also removed the revised CTAD deck from their website.

So now all we are left with is a couple meaningless Odds Ratios and a CDR-SB chart that clearly shows a non linear time/response evolution ending with a slightly positive outcome with a rather unimpressive p-value.

You can't have your cake and eat it, I guess with the ways of Anavex.